Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Esmolol + sodium nitroprusside** is a combination used intravenously for acute cardiovascular management, particularly perioperative and intraoperative blood pressure and heart rate control. - **Esmolol** is a cardioselective beta-1 adrenergic receptor antagonist, acting as a rapid-onset, short-duration beta-blocker to reduce heart rate and suppress sympathetic stimulation[5]. - **Sodium nitroprusside** is a potent direct vasodilator that increases nitric oxide bioavailability, thus causing rapid and short-acting arterial and venous dilation, resulting in decreased blood pressure. This admixture is compatible and stable for at least 24 hours under protected conditions[1][4]. In clinical settings, esmolol is often used to counteract the reflex tachycardia induced by sodium nitroprusside during induced hypotension or controlled hypotensive anesthesia[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on esmolol + sodium nitroprusside.